- Home
- KYNB vs SKYE Comparison
KYNB vs SKYE Comparison
Compare KYNB & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KYNB | SKYE |
|---|---|---|
| Founded | 1993 | 2012 |
| Country | United States | United States |
| Employees | 34 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 24.7M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | KYNB | SKYE |
|---|---|---|
| Price | $7.31 | $0.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 15.6K | ★ 122.6K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.32 | $0.57 |
| 52 Week High | $9.58 | $4.99 |
Technical Indicators
Market Signals| Indicator | KYNB | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 54.14 | 36.13 |
| Support Level | $6.59 | $0.57 |
| Resistance Level | $7.41 | $0.84 |
| Average True Range (ATR) | 0.30 | 0.04 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 53.68 | 33.13 |
Price Performance
Historical ComparisonAbout KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.